LifeStance Health Group Inc · Q1 2022 earnings

Briefing

LifeStance's first quarter results reflected a solid performance driven by disciplined execution and strong clinician growth.

LifeStance Health Group, Inc. reported revenue of $203.1 million, a 42% increase compared to the previous year. The company's clinician base grew by 51% to 4,989. Net loss was $62.3 million, primarily due to stock-based compensation expense. The company reaffirmed its full year 2022 revenue guidance of $865 million to $885 million.

• Revenue increased by 42% to $203.1 million.
• Total clinicians grew by 51% to 4,989, with a net increase of 199 in the first quarter.
• Net loss was $62.3 million, impacted by stock-based compensation expense of $59.9 million.
• Adjusted EBITDA was $12.5 million, remaining relatively flat compared to the prior year.

Headline financials

Revenue & EPS history

LifeStance is reiterating its guidance for 2022 revenue of $865 million to $885 million, Center Margin of $240 million to $255 million, and Adjusted EBITDA of $63 million to $67 million. For the second quarter of 2022, the company expects revenue of $209 million to $214 million, Center Margin of $57 million to $61 million, and Adjusted EBITDA of $12 million to $15 million.